Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional

CBT4CBT for Office Based Buprenorphine

NCT03580902
Conditions
Opioid-use Disorder
Interventions
CBT4CBT-Buprenorphine, Buprenorphine/naloxone
Behavioral · Drug
Lead sponsor
CBT4CBT, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Opioid Use Disorder, Opioid Dependence, Chronic Pain
Interventions
Buprenorphine/Naloxone
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Substance-related Disorders, HIV Risk Behavior
Interventions
Therapeutic Workplace, Methadone, Buprenorphine
Behavioral · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Conditions
Chronic Pain
Interventions
buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Induction for Fentanyl Dependent Opioid Users

NCT04794790
Conditions
Opioid Dependence Fentanyl
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Harrisburg, Pennsylvania
Completed Not applicable Interventional Results available

SMART Effectiveness Trial

NCT04464421
Conditions
Opioid-use Disorder, Opioid Dependence, Treatment Adherence
Interventions
Contingency Management (CM), Brief Motivational Intervention + Substance Free Activities Session + Mindfulness-Based Adherence Promotion (BSM)
Behavioral
Lead sponsor
Karen Derefinko, PhD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Opioid-use Disorder
Interventions
OXD01 digital therapy, Standard of Care
Device · Other
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
21
States / cities
Birmingham, Alabama • Oceanside, California • San Diego, California + 17 more
Conditions
Opioid Use Disorder, Opioid Withdrawal
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
United Health Services Hospitals, Inc.
Other
Eligibility
18 Years and older
Enrollment
20 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Binghamton, New York
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
19 Years to 57 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Healthy Volunteer, Opioid-use Disorder
Interventions
INDV-2000, Placebo, SUBOXONE® sublingual film
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Opiate Addiction, Refractory Pain
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Buffalo, New York
Completed Not applicable Interventional Accepts healthy volunteers

Abuse Potential of Buprenorphine and Naloxone in Non-Dependent Opioid Users

NCT00158236
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine, Buprenorphine and Naloxone, Hydromorphone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome, Opiate Addiction, Drug Dependence
Interventions
buprenorphine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Pain
Interventions
buprenorphine/naloxone, opioid dose escalation
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Conditions
Buprenorphine, Pain
Interventions
Buprenorphine
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Timeline
2017 – 2018
U.S. locations
2
States / cities
Rockville, Maryland • Silver Spring, Maryland
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Heroin Dependence
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 62 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Addiction Opiate, Chronic Pain, Fractures, Bone, Buprenorphine Dependence
Interventions
Sufentanil
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Morgantown, West Virginia